TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06698250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma designed to attach to and block CTLA-4, a protein that controls the activity of T cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Tremelimumab is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma designed to attach to and block CTLA-4, a protein that controls the activity of T cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Tremelimumab is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma designed to attach to and block CTLA-4, a protein that controls the activity of T cells
Study: NCT06547099

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical amyloid test
Description: Amyloid PET (florbetapir), CSF amyloid test, or blood amyloid test

Intervention type: OTHER
Intervention: Research blood collection
Description: Research blood assays for amyloid, tau, and neurodegeneration

Intervention type: OTHER
Intervention: Research blood collection
Description: Research blood assays for amyloid, tau, and neurodegeneration
Study: NCT04491578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP programme Have a Say
Description: Each dyad of participants will receive a 4-session ACP programme, which consists of educational components, guided reflection, and dyadic ACP discussion, guided by ACP facilitators and an ACP booklet. It is composed of 2 group-based sessions and 2 dyadic discussions. One hour for each session. The group-based sessions are nurse-led, in which dyads of participants will be provided with information about the trajectory of dementia, their future healthcare needs and caring options. Their values and care preferences on future care will be elicited in a consistent manner. The dyadic sessions are led by trained ACP facilitator. Dyads of participants will be supported to have an individualized ACP discussion. By the end of the programme, each dyad of participants will be given an ACP booklet documenting the ACP process.
Study: NCT05365152

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal Replacement
Description: Meal Replacement
Study: NCT05385822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: * Isolated, quite light tension in the pelvic floor 10 times, where the tension is released immediately~* Constant tension for 30 seconds twice, with a 30-second pause~* Total relaxation for 1 minute They must perform these exercises once a day during the trial period of 3 months
Study: NCT05327647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Induction intravesical BCG with bicalutamide 150 mg for 90 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: Induction BCG
Study: NCT05632575

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Virtual Promotoras Program
Description: Participants will receive a unique participant code from the virtual promotoras (i.e., patient educators and navigators), to access the VIP mobile phone app intervention. This will give them access to the three main components of the VIP intervention:~1. Educational Modules (8 evidence-based educational modules made by the VPs),~2. Sexual and Reproductive Health Plan (SRHP): Quiz-style instrument to help the participant set goals for her sexual health and develop a set of questions to ask her provider.~3. Virtual Promotora's (VP) chat room.: Opportunity for participant to ask any questions that she may have about sexual health (SH) or sexual healthcare access (SHCA), refine her SRHP. The VP will also help her make her appointment for her clinical visit with one of the local free clinics which do not require insurance and are youth-friendly, and practice having the conversation that she wants to have with her clinical provider.
Study: NCT06564558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Strengthening Exercises
Description: Individuals in the experimental group will carry out 3 sets of 10 repetitions or what is tolerated within a Borg scale intensity of 4-5 with 70-80% of perceived exertion with appropriately picked elastic bands. The exercises include: Shoulder horizontal abduction; Shoulder elevation; Back Extensions over a plinth; Shoulder extension exercises; One arm and opposite leg lifts from quadruped; and finally bilateral arm lifts with upper thoracic extension from prone (superman exercise).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Spine Stretching
Description: Participants will be instructed to do two exercises: Firstly, to lay supine with and hinge the thoracic spine over a roller placed in a way that would ensure the patient is forward lying and not completely supine. The participant will be instructed to maintain hinging until a stretch or pressure feeling is felt in the midback and hold this position for 3 sets of 30 seconds. Secondly, the patient was asked to be in a seated position, clasp the hands together and behind the head while arching backward over the chair and looking up. This exercise will be done for 3 sets of 20-30 repetitions with a slight hold time at the end of the movement. All interventions will be carried out for 45 minute sessions 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Spine Mobilization
Description: The patient will be seated with both hands clasped at shoulder level. An experienced and blinded therapist standing homolateral to the patient supports the clasped hands with one arm while placing the other hand was placed at different thoracic regions until the thoracolumbar junction. Specifically, the dorsal aspect of the index finger and pad of the thumb were used to create a fixation point at the junction. Following that, gentle extension-directed glides (postero-anterior) will be done by the therapist for 3 sets of 10 repetitions or until tolerated by the patient.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Postural Correction
Description: comprised an hour of social interaction with similar participants where a blinded therapist will provide educational tips for dealing with kyphosis along with educational reading material for each participant.
Study: NCT05571293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab, a CTLA-4 inhibitor, will be administered prior to surgical resection as described in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab, a CTLA-4 inhibitor, will be administered prior to surgical resection as described in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab, a CTLA-4 inhibitor, will be administered prior to surgical resection as described in the arm description.
Study: NCT04500548

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of tissue samples

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05655455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking group: 1.group
Description: In the study, walking attempt will be applied (2 x40 min/week and 6 weeks in total) to the 1st intervention group (n:15) in a gym. It will be given by a specialist in public health nursing. (first researcher)
Study: NCT06547099

Intervention type: OTHER
Intervention: Cognitive assessments
Description: Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)

Intervention type: OTHER
Intervention: Cognitive assessments
Description: Clinical Dementia Rating (CDR) or electronic Clinical Dementia Rating (eCDR); Montreal Cognitive Assessment (MoCA)
Study: NCT05571293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab, a PD-1 inhibitor, will be administered prior to surgical resection as described in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab, a PD-1 inhibitor, will be administered prior to surgical resection as described in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab, a PD-1 inhibitor, will be administered prior to surgical resection as described in the arm description.
Study: NCT05140421

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Data to Suppression (D2S)
Description: Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
Study: NCT05212168

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-G1.1-NN
Description: Norovirus GI.1 Norwalk VP1 Vaccine, Oral E1-/E3-Deleted Replication Defective Recombinant Adenovirus 5 with dsRNA Adjuvant
Study: NCT05140421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Data to Suppression (D2S)
Description: Intervention components include (1) reporting and (2) capacity building to facilitate identification of and follow-up with PWH who are in care but virally unsuppressed. The NYC Health Department will send client-level, surveillance-based reports on individual clients' viral suppression status to those clients' current Ryan White Part A behavioral health and housing service providers. The Health Department will also provide capacity building and technical assistance (TA) support to service providers on following up with clients flagged as unsuppressed, and on addressing barriers to viral suppression through root cause analyses and the development and implementation of D2S quality improvement projects. The intervention components are all delivered to Ryan White Part A providers by the Health Department, in order to enhance program resources to achieve and maintain viral suppression in the Ryan White Part A client population in NYC.
Study: NCT05212168

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Oral tablets similar in appearance and number to active vaccine tablets

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Norovirus GI.1 Norwalk Virus Inoculum
Description: Norwalk Virus Inoculum Lot 01-09NV

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Norovirus GI.1 Norwalk Virus Inoculum
Description: Norwalk Virus Inoculum Lot 01-09NV
Study: NCT06017947

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Music care
Description: 20 min music listening during transportation to hospital
Study: NCT05295368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Intervention includes four components 1) training nurses as health coaches for motivational conversation and CKD specific lifestyle counseling on diet and exercise, using hybrid follow-up approach of in-person, telephone, and secure video sessions; 2)Training physicians in algorithm-based standardized management of CKD and hybrid care delivery;3) subsidy on sodium-glucose transport protein-2 inhibitors (SGLT-2i) for CKD; and 4) regular CKD case review meetings.
Study: NCT06363448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yamani Technique versus Prolene Mesh for Intraocular Lens Scleral Fixation in Aphakia
Description: Patients were divided into two groups to undergo classic ab externo two-point scleral fixation or flanged haptics as described by Yamani or the 2\*2 proline mesh technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Yamani Technique versus Prolene Mesh for Intraocular Lens Scleral Fixation in Aphakia
Description: Patients were divided into two groups to undergo classic ab externo two-point scleral fixation or flanged haptics as described by Yamani or the 2\*2 proline mesh technique.
Study: NCT04149743

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care with Hemotag
Description: Comparison of outcomes
Study: NCT06203223

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ova-max
Description: use Ova-max 3 months prior to treatment initiation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: use placebo 3 months prior to treatment initiation
Study: NCT05495022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) program
Description: Mindfulness-based stress reduction (MBSR) program will be applied by the researcher to the midwives in the experimental group. Conscious Awareness-Based Stress Reduction will be applied by the researcher (S.Ö.C.) who has received training (16 hours) and has a certificate in this field. Stress reduction program based on mindfulness is planned as 2 sessions per week for 4 weeks, a total of 8 sessions. Each session is planned to last 40-60 minutes on average. Sessions will continue as individual and group sessions by determining the days when midwives are available online.
Study: NCT05655455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dance and movement therapy group: 2.group
Description: In the study, dance and movement therapy will be applied (2 x40 min/week and 6 weeks in total) to the 2nd intervention group (n:15) in a gym. It will be given by a specialist in psychiatric nursing.
Study: NCT06001723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forest Therapy
Description: Forest healing activities are guided by professionals, allowing participants to engage in a two-hour sensory experience within the forest environment. This includes activities such as stacking leaves and stones, closing their eyes to listen to sounds, engaging in physical stretches, blindfolded tree identification, connecting with tree companions, creating earth mandalas, and partaking in tea ceremonies and sharing insights.
Study: NCT05896241

Intervention type: OTHER
Intervention: non-interventional study
Description: non-interventional study

Intervention type: OTHER
Intervention: non-interventional study
Description: non-interventional study
Study: NCT05230667

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection (PRP group)
Description: Patients in the PRP group will receive both shoulder joint (GHJ) and SASD bursa injection for one time. PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. About 2ml PRP and 3ml platelet poor plasma (PPP) will be extracted, then 4ml 1% xylocaine will be added to make 9ml injectate. 6ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. Another 3ml injectate will be injected into the SASD bursa of the affected shoulder with a 3.8 cm 22-gauge needle under US guidance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRP injection (PRP group)
Description: Patients in the PRP group will receive both shoulder joint (GHJ) and SASD bursa injection for one time. PRP will be prepared by taking 10ml venous blood which is then mixed with 2ml of thrombin and centrifuged in a specially designed tube at 3400 rotations per minute (rpm) for 15 minutes. About 2ml PRP and 3ml platelet poor plasma (PPP) will be extracted, then 4ml 1% xylocaine will be added to make 9ml injectate. 6ml injectate will be injected into the posterior GHJ with a 7 cm 23-gauge needle under ultrasound (US) guidance. Another 3ml injectate will be injected into the SASD bursa of the affected shoulder with a 3.8 cm 22-gauge needle under US guidance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection (CS group)
Description: Three ml triamcinolone (1ml= 10mg), 4ml 1% xylocain, and 2ml normal saline to make a 9ml injectate is injected into the affected shoulder (6ml to posterior GHJ and 3 ml to SASD bursa). The techniques of injection are the same as those used in the PRP injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection (CS group)
Description: Three ml triamcinolone (1ml= 10mg), 4ml 1% xylocain, and 2ml normal saline to make a 9ml injectate is injected into the affected shoulder (6ml to posterior GHJ and 3 ml to SASD bursa). The techniques of injection are the same as those used in the PRP injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline injection (NS group)
Description: Four 4ml 1% xylocaine mixed with 5ml normal saline will be injected into the affected GHJ (6ml) and SASD bursa (3ml). The techniques of injection are the same as those used in the PRP injection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline injection (NS group)
Description: Four 4ml 1% xylocaine mixed with 5ml normal saline will be injected into the affected GHJ (6ml) and SASD bursa (3ml). The techniques of injection are the same as those used in the PRP injection.
Study: NCT04883944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Mother will be involved in implementing the non-pharmacological techniques during the performance of the heel stick procedure as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding;~* exposure to maternal voice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care group
Description: A second nurse will perform the non-pharmacological techniques during the performance of the heel stick procedure without the maternal involvement as follow:~* swaddling;~* non-nutritive sucking with pacifier in infants with PMA \< 32 weeks;~* nutritional sucking with sucrose and/or breast milk in infants with PMA ≥ 32 weeks;~* holding.
Study: NCT06547606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants in the control group will recieve usual care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control group will recieve usual care.
Study: NCT05475821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-990
Description: Oral Tablet
Study: NCT05818982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib will be administered orally at 40 mg per day (qd) in each 6-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan, intravenous drip, 140-180mg/㎡, D1, Q14D
Study: NCT05098002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness program
Description: 6 week class designed to improve psychological well-being
Study: NCT04752488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR)
Description: The home exercise program will be educated to the patient on the first day. Exercises for isometric and isotonic strengthening, stretching, and stabilization of the neck muscles will be given. Exercises will be presented to the patients in audio-video format and detailed instructions with explanations. The exercise protocol will also be the same as in the conventional rehabilitation group. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation (CR)
Description: The home exercise program will be educated to the patient on the first day. Isometric and isotonic strengthening, stretching and stabilization exercises for the neck muscles will be given. Exercise information form including explanation and picture of the exercises will be given to the patients. Patients will be asked to do the exercises once a day for 8 weeks and 10 repetitions each.
Study: NCT04858659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK101
Description: 1 tablet at each time, 2 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PK101-002
Description: 1 tablet at each time, 2 times a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PK101 placebo
Description: 1 tablet at each time, 2 times a day
Study: NCT06159764

Intervention type: PROCEDURE
Intervention: Cardioneuroablation
Description: radiofrequency ablation to destroy cardiac ganglionated plexi located in epicardial fat pads around the atrias
Study: NCT05475821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-990
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-990
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-990
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-990
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-990
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-990
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-990
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-990
Description: Oral Tablet